NORD gratefully acknowledges Dr. Helen Leonard, Telethon Kids Institute, Perth, Australia; Prof. John Christodoulou, NSW Centre for Rett Syndrome Research, Children's Hospital at Westmead, Sydney, Australia; and Dr. Katheryn Elibri Frame, International Foundation for CDKL5 Research, for assistance in the preparation of this report.
Seizures are prominent in genetically confirmed CDKL5 patients, and are usually severe, and include infantile spasms, myoclonic seizures, tonic-clonic seizures, and most particularly epileptic encephalopathy.
Clinical syndromes where CDKL5 mutations should be considered include:
– infantile onset seizures with poor neurocognitive development (epileptic encephalopathy)
– infantile spasms in females and males
– atypical Rett syndrome (Hanefeld variant)
Bahi-Buisson and colleagues (2008) reported on the natural history of epilepsy in 12 patients with CDKL5 mutations, and proposed a 3-stage model of the epileptic phenotype. This model describes early epilepsy in the first stage (median age of 4 weeks), epileptic encephalopathy in the second stage and tonic seizures and late myoclonic epilepsy in the third.
Note that to date CDKL5 mutations have only rarely been found to be associated with autism and intellectual disability in the absence of seizures, and have not been described in patients with classical Rett syndrome.
Artuso et al. (2010) developed clinical criteria for what they coined “the early onset seizure variant of Rett syndrome” caused by mutations in CDKL5. Consistent with previous research but only based on a series of nine cases, they outlined the cardinal features of this variant as irritability in the perinatal period, early epilepsy, hand stereotypies, severely impaired psychomotor development and severe hypotonia. In contrast to classical Rett syndrome they also commented on the absence of a classic regression period, the poor eye contact, generally normal head circumference and other growth parameters and relative absence of autonomic dysfunction.
Other symptoms of a CDKL5 disorder often include:
– Low muscle tone
– Hand wringing movements or mouthing of the hands
– Marked developmental delay
– Limited or absent speech
– Lack of eye contact or poor eye contact
– Gastroesophageal reflux
– Small, cold feet
– Breathing irregularities such as hyperventilation
– Grinding of the teeth
– Episodes of laughing or crying for no reason
– Low/Poor muscle tone
– Very limited hand skills
– Some autistic-like tendencies
– Cortical Visual Impairment (CVI), aka “cortical blindness”
– Eating/drinking challenges
– Sleep difficulties
– Characteristics such as a sideways glance, and habit of crossing leg
In 2012 Fehr and colleagues capitalized on available data from an international data collection to describe the clinical profile of the CDKL5 disorder and compare it with Rett syndrome. Information on individuals with CDKL5 mutations (n=86) and females with MECP2 mutations (n=920) was sourced from the InterRett database. Most individuals with CDKL5 mutations had severe developmental delay and onset of seizures before the age of three months. Less than one quarter actually met the criteria for the early-onset seizure atypical form of Rett syndrome. Seizures and sleep disturbances were more common than in those with MECP2 mutations while features of regression and spinal curvature or scoliosis were less common.
A shared physical resemblance was also observed between females with the CDKL5 disorder, with the most consistent features being a prominent/broad forehead, deep-set but ‘large-appearing’ eyes, full lips and tapered fingers. Males were more likely to have an unusual facial appearance, with distinctly anteverted nares (upturned tip of the nose), and several males also had a short philtrum (the vertical groove between the nose and upper lip) and everted upper lip. Previous studies of the CDKL5 disorder have also reported features such as large deep-set eyes, strabismus, high forehead, full lips, wide mouth, widely spaced teeth and a high palate.
The International CDKL5 Disorder Database was established in September 2012 and is continuing to collect data from families with a child with confirmed CDKL5 disorder throughout the world. This database provides the capacity to collect important information which will help us better understand this disorder and the associated comorbidities. The first output from the database has examined developmental milestones in 127 children with the CDKL5 disorder. Overall attainment of milestones was extremely delayed. For example, the median age of independent sitting for girls was 36 months and by five years only three quarters had learned to sit independently. About a quarter of girls had learned to walk independently by the age of four and a half years. Overall males had more impaired development and more delayed milestones. Relationships with genotype (ie type of mutation) were also explored but difficult to determine because of the large number of unique mutations and the few that are shared by more than one individual.
The CDKL5 gene provides instructions for making a protein that is essential for normal brain development. Although little is known about the protein’s function, it may play a role in regulating the activity of other genes, including the MECP2 gene associated with Rett syndrome. The CDKL5 protein acts as a kinase, which is an enzyme that changes the activity of other proteins by adding oxygen and phosphate atoms (a phosphate group) at specific positions. Researchers have not yet determined which proteins are targeted by the CDKL5 protein.
Most of the CDKL5 gene mutations are “de novo”, meaning that they occur spontaneously, and are not passed down through families. However, rare families in which multiple siblings were affected with the same mutation, have been reported.
CDKL5 mutations have been identified in many ethnic groups, with more females than males being reported with an approximate ratio of 5:1, but with males usually being more severely affected.
Diagnosis is initially suspected based on symptoms, history and physical exam. CDKL5 is confirmed by molecular genetic testing for CDKL5 mutations.
Currently no curative or specific therapies are available for individuals with the CDKL5 disorder so medical management is symptomatic and supportive. A multidisciplinary team approach is the most effective way to deliver necessary treatments, aimed at maximizing the individual’s abilities and facilitating any skills that may be emerging. An emphasis should be placed on early intervention therapies such as physical therapy, occupational therapy, and speech and augmentative communication therapy. Important aspects of management include psychosocial support for the family, development of an appropriate education plan, and assessment of available community resources.
It is important to have the involvement of a dietitian with expertise in the management of individuals with intellectual disability, so that optimal nutritional status can be maintained. Some affected individuals are able to feed orally, however many require the assistance of enteral nutritional support
Most individuals with CDKL5 do not develop verbal expressive language, and so other forms of communication should be considered, including communication boards, technical devices, and switch activated systems to facilitate choice making and environmental access.
Seizure control is challenging, and is often the most difficult health issue to manage. No one anticonvulsant has been found to be uniformly effective, and often multiple anticonvulsants are needed. Vagal nerve stimulation (VNS) has also been used with improvements in some patients. Dietary modifications, such as the ketogenic diet, have shown variable improvement in some individuals. However, these rigid dietary changes must only be implemented under close medical supervision and can be demanding on families.
Many affected individuals develop scoliosis, although as with many comorbidities in this disorder, there is little available literature on prevalence or natural hitory. Bracing may be suggested for some, while others will need to have surgical intervention. Increased muscle tone may develop, placing the individual at risk of developing foot deformities and shortened heel cords. It is important to maintain ambulation as much as possible in those who have learned to walk, and ankle orthoses may prove beneficial to prevent these orthopedic problems from developing. Physiotherapy/physical therapy is also of benefit in improving overall muscle tone, trunk stability, strengthening, balance, prevention of foot deformities, maintaining foot alignment and keeping heel cords lengthened.
There is still much to be learned about how CDKL5 mutations affect brain function. Because the biology of the CDKL5 protein and its deficiency is so poorly understood at present, there are currently no investigational therapies being studied. Recent research suggests that there is a functional interaction between CDKL5 and MECP2, and it may be that therapies currently being trialed in MECP2 mutation-positive Rett syndrome patients may have a therapeutic role in individuals with CDKL5 mutations. However, potential treatments will first need to be tested using animal models.
A catalogue of CDKL5 sequence variations, including pathogenic mutations, nonpathogenic polymorphisms, and sequence variations of uncertain significance can be found at the RettBASE website (http://mecp2.chw.edu.au).
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site. For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office: Tollfree: (800) 411-1222 TTY: (866) 411-1010 Email: email@example.com For information about clinical trials sponsored by private sources, contact: www.centerwatch.com. For information about clinical trials conducted in Europe, contact: https://www.clinicaltrialsregister.eu/
Fehr S, Leonard H, Ho G, Williams S, de Klerk N, Forbes D, Christodoulou J, Downs J. There is variability in the attainment of developmental milestones in the CDKL5 disorder. Journal of Neurodevelopmental Disorders. 2015;7:2-.
Mueller A, Jansen C, Selch C, Bast T, Lotte J, Guerrini R, Albers J, Muhle H, Auvin S, Korenke GC, Philip S, Keimer R, Striano P, Wolf NI, Puest B, Thiels C, Fogarasi A, Waltz S, Kurlemann G, Kovacevic-Preradovic T, Ceulemans B, Berweck S, Staudt M, Kluger G. Retrospective evaluation of antiepileptic drugs and ketogenic diet in 40 patients with CDKL5 mutations: low long-term efficacy. Epilepsia. 2014;55:178-9.
Fehr S, Wilson M, Downs J, Williams S, Murgia A, Sartori S, Vecchi M, Ho G, Polli R, Psoni S, Bao X, de Klerk N, Leonard H, Christodoulou J. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. European Journal of Human Genetics. 2013;21(3):266-73.
Hagebeuk EEO, Van den Bossche RAS, De Weerd AW. Respiratory and sleep disorders in female children with atypical Rett syndrome caused by mutations in the CDKL5 gene. Developmental Medicine and Child Neurology. 2013;55(5):480-4.
Sharma S, Prasad AN. Genetic Testing of Epileptic Encephalopathies of Infancy: An Approach. Canadian Journal of Neurological Sciences. 2013;40(1):10-6.
Castren M, Gaily E, Tengstrom C, Lahdetie J, Archer H, Ala-Mello S. Epilepsy caused by CDKL5 mutations. European Journal of Paediatric Neurology. 2011;15(1):65-9.
Klein KM, Yendle SC, Harvey AS, Antony JH, Wallace G, Bienvenu T, Scheffer IE. A distinctive seizure type in patients with CDKL5 mutations: hypermotor-tonic-spasms sequence. Neurology. 2011;76(16):1436-8.
Artuso R, Mencarelli MA, Polli R, Sartori S, Ariani F, Pollazzon M, et al. Early-onset seizure variant of Rett syndrome: Definition of the clinical diagnostic criteria. Brain Dev. 2010 Apr 9;32(1):17-24. http://www.ncbi.nlm.nih.gov/pubmed/19362436
White R, Ho G, Schmidt S, Scheffer IE, Fischer A, Yendle SC, et al. Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders. Twin Res Hum Genet. 2010 Apr;13(2):168-78. http://www.ncbi.nlm.nih.gov/pubmed/20397747
Psoni S, Willems PJ, Kanavakis E, Mavrou A, Frissyra H, Traeger-Synodinos J, et al. A novel p.Arg970X mutation in the last exon of the CDKL5 gene resulting in late-onset seizure disorder. Eur J Paediatr Neurol. 2010 Mar;14(2):188-91.
Mei D, Marini C, Novara F, Bernardina BD, Granata T, Fontana E, et al. Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy. Epilepsia. 2010 Apr;51(4):647-54.
Buoni S, Zannolli R, Hayek J. CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. Neurology. 2009;73(1):76-7.
Nemos C, Lambert L, Giuliano F, Doray B, Roubertie A, Goldenberg A, et al. Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature. Clin Genet. 2009 Oct;76(4):357-71. http://www.ncbi.nlm.nih.gov/pubmed/19793311
Bahi-Buisson N, Kaminska A, Boddaert N, Rio M, Afenjar A, Gerard M, et al. The three stages of epilepsy in patients with CDKL5 mutations. Epilepsia. 2008 Feb 7;49(6):1027-37. http://l2c2.isc.cnrs.fr/publications/files/bahi.pdf
Elia M, Falco M, Ferri R, Spalletta A, Bottitta M, Calabrese G, et al. CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. Neurology. 2008 Sep 23;71(13):997-9. http://www.ncbi.nlm.nih.gov/pubmed/18809835
Bahi-Buisson N, Nectoux J, Rosas-Vargas H, Milh M, Boddaert N, Girard B, et al. Key clinical features to identify girls with CDKL5 mutations. Brain. 2008 Oct;131(Pt 10):2647-61. http://www.ncbi.nlm.nih.gov/pubmed/18790821
Bertani I, Rusconi L, Bolognese F, Forlani G, Conca B, De Monte L, et al. Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation. J Biol Chem. 2006 Aug 24;281(42):32048-56. http://www.ncbi.nlm.nih.gov/pubmed/16935860
Buoni S, Zannolli R, Colamaria V, Macucci F, di Bartolo RM, Corbini L, et al. Myoclonic encephalopathy in the CDKL5 gene mutation. Clin Neurophysiol. 2006 Jan;117(1):223-7. http://www.ncbi.nlm.nih.gov/pubmed/16326141
Archer HL, Evans J, Edwards S, Colley J, Newbury-Ecob R, O’Callaghan F, et al. CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. J Med Genet. 2006 Sep;43(9):729-34. http://www.ncbi.nlm.nih.gov/pubmed/16611748
Lin C, Franco B, Rosner MR. CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders. Hum Mol Genet. 2005 Dec 15;14(24):3775-86. http://hmg.oxfordjournals.org/content/14/24/3775.full.pdf
Scala E, Ariani F, Mari F, Caselli R, Pescucci C, Longo I, et al. CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms. J Med Genet. 2005 Feb;42(2):103-7. http://www.ncbi.nlm.nih.gov/pubmed/15689447
Mari F, Azimonti S, Bertani I, Bolognese F, Colombo E, Caselli R, et al. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early seizure variant of Rett syndrome. Hum Mol Genet. 2005 May 25;14(14):1935-46. http://www.ncbi.nlm.nih.gov/pubmed/15917271
Evans JC, Archer HL, Colley JP, Ravn K, Nielsen JB, Kerr A, et al. Early onset seizures and Rett-like features associated with mutations in CDKL5. Eur J Hum Genet. 2005 Oct;13(10):1113-20. http://www.nature.com/ejhg/journal/v13/n10/full/5201451a.html
Weaving LS, Christodoulou J, Williamson SL, Friend KL, McKenzie OL, Archer H, et al. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet. 2004 Dec;75(6):1079-93. http://www.ncbi.nlm.nih.gov/pubmed/15492925
Tao J, Van Esch H, Hagedorn-Greiwe M, Hoffmann K, Moser B, Raynaud M, et al. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am J Hum Genet. 2004 Dec;75(6):1149-54. http://www.ncbi.nlm.nih.gov/pubmed/15499549
Kalscheuer VM, Tao J, Donnelly A, Hollway G, Schwinger E, Kubart S, et al. Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. Am J Hum Genet. 2003 Jun;72(6):1401-11. http://www.ncbi.nlm.nih.gov/pubmed/12736870
Huopaniemi L, Tyynismaa H, Rantala A, Rosenberg T, Alitalo T. Characterization of two unusual RS1 gene deletions segregating in Danish retinoschisis families. Hum Mutat. 2000 Oct;16(4):307-14. http://www.ncbi.nlm.nih.gov/pubmed/11013441
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100